Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)‐Negative Breast Cancer

Documenti analoghi

• Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches
  di: Zoey Tang, et al.
  Pubblicazione: (2026)
• Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato‐ DXd ), a TROP2 ‐Directed Antibody‐Drug Conjugate, in Patients With Advanced Solid Tumors
  di: Ying Hong, et al.
  Pubblicazione: (2025)
• Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative ( HR +/ HER2 −) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study
  di: Debu Tripathy, et al.
  Pubblicazione: (2026)
• Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
  di: KyoungSoo Lim, et al.
  Pubblicazione: (2024)
• Modified Delphi Study on Oral Mucositis/Stomatitis Prevention and Management in Patients Receiving Datopotamab Deruxtecan
  di: Paolo Bossi, et al.
  Pubblicazione: (2026)